Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18.

OBJECTIVE We sought to develop a novel biochemical assay and algorithm for the prenatal evaluation of risk for fetal trisomy 21 (T21) and trisomy 18 (T18) using cell-free DNA obtained from maternal blood. STUDY DESIGN We assayed cell-free DNA from a training set and a blinded validation set of pregnant women, comprising 250 disomy, 72 T21, and 16 T18 pregnancies. We used digital analysis of selected regions in combination with a novel algorithm, fetal-fraction optimized risk of trisomy evaluation (FORTE), to determine trisomy risk for each subject. RESULTS In all, 163/171 subjects in the training set passed quality control criteria. Using a Z statistic, 35/35 T21 cases and 7/7 T18 cases had Z statistic >3 and 120/121 disomic cases had Z statistic <3. FORTE produced an individualized trisomy risk score for each subject, and correctly discriminated all T21 and T18 cases from disomic cases. All 167 subjects in the blinded validation set passed quality control and FORTE performance matched that observed in the training set correctly discriminating 36/36 T21 cases and 8/8 T18 cases from 123/123 disomic cases. CONCLUSION Digital analysis of selected regions and FORTE enable accurate, scalable noninvasive fetal aneuploidy detection.

[1]  D. Bianchi,et al.  Sharpening the Tools: A summary of a National Institutes of Health workshop on new technologies for detection of fetal cells in maternal blood for early prenatal diagnosis , 2006, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[2]  F. Bischoff,et al.  Prenatal diagnosis with use of fetal cells isolated from maternal blood: five-color fluorescent in situ hybridization analysis on flow-sorted cells for chromosomes X, Y, 13, 18, and 21. , 1998, American journal of obstetrics and gynecology.

[3]  N. Wald.  Prenatal screening for open neural tube defects and Down syndrome: three decades of progress , 2010, Prenatal diagnosis.

[4]  W. J. Conover,et al.  Practical Nonparametric Statistics , 1972 .

[5]  Peiyong Jiang,et al.  Noninvasive Prenatal Diagnosis of Fetal Trisomy 18 and Trisomy 13 by Maternal Plasma DNA Sequencing , 2011, PloS one.

[6]  J. Gaughan,et al.  Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood--a meta-analysis. , 2006, American journal of obstetrics and gynecology.

[7]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[8]  K. Moise,et al.  Use of maternal plasma for noninvasive determination of fetal RhD status. , 2004, American journal of obstetrics and gynecology.

[9]  H. Cuckle.  Integrating antenatal Down's syndrome screening , 2001, Current opinion in obstetrics & gynecology.

[10]  Stephen R. Quake,et al.  Sensitivity of Noninvasive Prenatal Detection of Fetal Aneuploidy from Maternal Plasma Using Shotgun Sequencing Is Limited Only by Counting Statistics , 2010, PloS one.

[11]  K. Nicolaides,et al.  Screening for chromosomal defects , 2003, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[12]  K. Nicolaides.  Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. , 2004, American journal of obstetrics and gynecology.

[13]  A. Caughey,et al.  Chorionic Villus Sampling Compared With Amniocentesis and the Difference in the Rate of Pregnancy Loss , 2006, Obstetrics and gynecology.

[14]  A. Rudnicka,et al.  First-trimester or second-trimester screening, or both, for Down's syndrome. , 2005, New England Journal of Medicine.

[15]  C. Cantor,et al.  Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma , 2008, Proceedings of the National Academy of Sciences.

[16]  ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. , 2007, Obstetrics and gynecology.

[17]  Y. Ville,et al.  Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population. , 2006, American journal of obstetrics and gynecology.

[18]  W. Holzgreve,et al.  Detection of fetal messenger ribonucleic acid in maternal blood to determine fetal RhD status as a strategy for noninvasive prenatal diagnosis. , 1998, American journal of obstetrics and gynecology.

[19]  R. Rava,et al.  Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. , 2011, Clinical chemistry.

[20]  John W. Tukey,et al.  Exploratory Data Analysis. , 1979 .

[21]  ACOG Practice Bulletin No. 88, December 2007. Invasive prenatal testing for aneuploidy. , 2007, Obstetrics and gynecology.

[22]  L. Shulman.  The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives. , 2011, American journal of obstetrics and gynecology.

[23]  J. Royston.  An Extension of Shapiro and Wilk's W Test for Normality to Large Samples , 1982 .

[24]  Stanley F. Nelson,et al.  Dna Sequencing of Maternal Plasma to Detect Down Syndrome: An International Clinical Validation Study , 2012 .

[25]  M. Ehrich,et al.  Multiplexed analysis of circulating cell-free fetal nucleic acids for noninvasive prenatal diagnostic RHD testing. , 2011, American journal of obstetrics and gynecology.

[26]  L. Hunt,et al.  Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. , 2009, American journal of obstetrics and gynecology.

[27]  J. Egan,et al.  Down syndrome screening in the United States in 2001 and 2007: a survey of maternal-fetal medicine specialists. , 2009, American journal of obstetrics and gynecology.

[28]  R. Frydman,et al.  [Increased nuchal translucency with normal karyotype]. , 2007, Gynecologie, obstetrique & fertilite.

[29]  L. Shulman.  One small step and one giant leap for noninvasive prenatal screening: an editorial. , 2011, American journal of obstetrics and gynecology.

[30]  Kypros H Nicolaides,et al.  Screening for fetal aneuploidies at 11 to 13 weeks , 2011, Prenatal diagnosis.

[31]  H. C. Fan,et al.  Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood , 2008, Proceedings of the National Academy of Sciences.

[32]  T. Jenkins.  Chorionic villus sampling compared with amniocentesis and the difference in the rate of pregnancy loss. , 2007, Obstetrics and gynecology.

[33]  Wade A. Barrett,et al.  Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy , 2012, Prenatal diagnosis.

[34]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[35]  Stephen R Quake,et al.  Microfluidic digital PCR enables rapid prenatal diagnosis of fetal aneuploidy. , 2009, American journal of obstetrics and gynecology.

[36]  Lin Tang,et al.  Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. , 2011, American journal of obstetrics and gynecology.

[37]  J. Dungan,et al.  Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study , 2011 .

[38]  Tianjiao Chu,et al.  A novel approach toward the challenge of accurately quantifying fetal DNA in maternal plasma , 2010, Prenatal diagnosis.